Seaport Therapeutics and Hemab filed S-1 registration statements with the SEC within hours of each other, following Kailera's $210 million IPO pricing on the same trading day. The cluster marks the most concentrated biotech offering activity since Q1 2023, when fourteen healthcare companies pulledfilings after SVB's collapse.
Seaport, a neuroscience-focused developer backed by Atlas Venture and Frazier Life Sciences, is advancing SPN-830 for post-traumatic stress disorder and major depressive disorder. The Cambridge firm raised $225 million across three private rounds since inception in 2020. Hemab, developing hemophilia A therapies out of Shanghai and Boston, last raised $102 million in a Series C led by OrbiMed and Qiming Venture Partners in late 2022. Neither company disclosed offering size or valuation range in initial filings. Kailera, a gene therapy platform targeting kidney disease, priced 15 million shares at $14.00, the midpoint of its range, after narrowing guidance twice during roadshow.
The timing reflects two tactical shifts. First, Kailera's oversubscribed book—despite pricing below its July 2023 Series D valuation of $820 million—gives syndicate desks a live comp for loss-making assets with Phase II data. Seaport's lead program reported topline results in December showing statistically significant PTSD symptom reduction versus placebo; Hemab's HMB-001 is in Phase I/II trials with interim data expected Q2 2025. Second, the three-month Treasury yield dropped 47 basis points since October, compressing biotech discount rates enough to make 2026-27 monetization timelines viable again for crossover funds holding late-stage positions. OrbiMed, a common thread across all three cap tables, is sitting on $3.2 billion in unrealized life sciences positions per its Q3 2024 ADV filing.
The reopening is conditional. Biotech IPO proceeds totaled $1.8 billion in 2024, down 72 percent from 2021's $6.4 billion. The companies filing now are those with twelve-plus months of runway and catalysts landing before capital markets could freeze again. Seaport's cash position as of September 30 was $187 million, sufficient through mid-2026 without additional financing. Hemab's runway is tighter—$68 million in cash against a $9 million monthly burn as of its last disclosed financials in March 2024. That asymmetry suggests Hemab is testing whether investors will pay for earlier-stage China-US dual development risk, or whether it becomes a June withdrawal.
Allocators should track three variables over the next forty-five days. First, whether Seaport and Hemab price within 15 percent of their last private rounds—anything steeper signals the window is open only at distress levels. Second, whether either company expands offering size during roadshow, indicating genuine institutional demand rather than insider-backstopped survival rounds. Third, the performance of Kailera's stock through its first earnings report in May; if it trades below issue price after data updates, syndicates will reprice risk across the entire neuroscience and rare disease cohort. Two more S-1s are expected from VC-backed biotechs before April, both filed confidentially in Q4 2024.
The Kailera pricing matters less for its $210 million gross than for proving a single biotech company could clear underwriters' risk committees in March 2025. The next thirty days determine whether that was an exit, or a reopening.